Back to clinical trials listSarcomas

TANGENT (SNX-301-020)

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

Open at Paris since : 14/02/2025
Target : Adult
Phase : Phase III

Trial description

The primary efficacy objective of this study is to estimate the treatment effect of emactuzumab by ORR by 6 months from initiation of therapy in the blinded phase compared to placebo.;ORR according to RECIST v1.1 by 6 months from initiation of therapy based on independent, blinded central review

Url of the trial

Main investigator

SOPHIE PIPERNO-NEUMANN

Médecin

Contact